When treated for cancer, young patients don’t always get the information they need from doctors.
The genetic differences that distinguish men’s breast cancers may lead to new diagnosis and treatment options.
Socioeconomic status, race and other disparities among patients can affect cancer treatments and outcomes. Researchers are working to change that.
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.
Members of the public can submit comments to the U.S. Preventive Services Task Force (USPSTF) on its draft recommendation statement on sun protection until Nov. 6, 2017.
Opdivo (nivolumab) was granted a priority review to a supplemental biologics license application (sBLA) to treat patients with melanoma who have a high risk of disease recurrence after complete surgical resection, according to Bristol-Myers Squibb (BMS), the company that makes the drug.
More and more, treating HER2-positive breast cancers involves combining an array of drugs.
Genetics may play a role in chemotherapy-related fatigue, according to a recent study.
As mutations in more genes are linked to the development of cancer, tests that identify the glitches are growing more expansive — but some gray areas remain.